Johnson & Johnson to take over Actelion for $30 billion

Swiss biotech company Actelion announced Thursday it had agreed to be acquired by Johnson & Johnson in a $30 billion deal.

The all-cash offer, to acquire all of the outstanding shares of Actelion for $280 per share, payable in U.S. dollars, was unanimously approved by the Boards of Directors of both companies, Actelion and Johnson & Johnson said in a joint statement.

Source: Reuters